CNS Pharma(CNSP.US)

Company Encyclopedia
View More
name
CNS Pharma
CNSP.US
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company’s drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
4.691 T
CNSP.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CNS Pharmaceuticals Appoints Rami Levin as CEO

    CNS Pharmaceuticals Inc. has appointed Rami Levin as its new President and CEO, effective January 1, 2026, succeeding John Climaco. Levin brings experience from leadership roles at Saniona, ImStem Biotechnology, Sobi, Merck Serono, and Schering AG.

    Reuters·
    US
    CNSP
    -3.85%
    Reuters·
    US
    CNSP
    -3.85%

    CNS Pharmaceuticals Increases Authorized Shares for Growth

    CNS Pharmaceuticals announced an increase in authorized shares of common and preferred stock, approved at their Annual Meeting on November 17, 2025. This amendment aims to enhance the company's capital structure and provide flexibility for growth and investment. Analysts have a Buy rating with a $20 price target, though the company faces challenges in profitability and financial stability. Technical indicators suggest the stock is oversold, presenting potential for stabilization or recovery.

    Tip Ranks·
    US
    CNSP
    -3.85%
    Tip Ranks·
    US
    CNSP
    -3.85%

    CNS Pharmaceuticals Held Annual Shareholder Meeting

    CNS Pharmaceuticals Inc. held its Annual Shareholder Meeting on November 17, 2025. Shareholders approved amendments to the 2020 Equity Plan, increasing authorized shares for issuance. The board of directors was elected, and amendments to the Articles of Incorporation were approved, increasing authorized shares of common and preferred stock. This news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    CNSP
    -3.85%
    Reuters·
    US
    CNSP
    -3.85%

    CNS Pharmaceuticals: Promising Drug Pipeline and Strategic Plans Drive Buy Rating

    Jason McCarthy from Maxim Group maintains a Buy rating for CNS Pharmaceuticals, citing its promising drug pipeline and strategic plans. The lead program, TPI-287, shows potential for treating recurrent glioblastoma, with plans to expand trials. Despite Berubicin not meeting primary endpoints, it shows promise with a better safety profile. Strategic FDA discussions may aid approval. These factors, along with CNS's financial position and upcoming presentations, support McCarthy's optimistic outlook.

    Tip Ranks·
    US
    CNSP
    -3.85%
    Tip Ranks·
    US
    CNSP
    -3.85%

    CNS Pharmaceuticals Reports Financial Gains Amid Ongoing R&D

    CNS Pharmaceuticals reported Q3 earnings with significant financial gains. Cash and cash equivalents rose to $9.86 million, driven by successful financing activities. Despite a net loss of $9.89 million, the loss decreased from $11.68 million in 2024. Operating expenses also decreased. The company focuses on developing anti-cancer drugs TPI 287 and Berubicin, and remains committed to advancing clinical trials and exploring strategic opportunities.

    Tip Ranks·
    US
    CNSP
    -3.85%
    Tip Ranks·
    US
    CNSP
    -3.85%
    © 2026 Longbridge｜Disclaimer